Gupta, Sumati

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial

Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P., Powles, T., McDermott, D., Robbins, P. B., Chism, D. D., et al. (2018) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 260

Complicated grief and deficits in emotional expressive flexibility

Gupta, S., & Bonanno, G. A. (2011) · Journal of Abnormal Psychology

Grief, Bereavement, and Mental HealthDeath, Funerary Practices, and Mourning

Cited by 164

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers

Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 44

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Swami, U., Maughan, B. L., Boucher, K. M., Nordblad, B., Lloyd, J., Batten, J., Phunrab, T. K., Quertinmont, J., Kohli, M., Gupta, S., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 9